In vivo F-19 resonance spectroscopy measurements of trifluorinated neu
roleptics (fluphenazine and trifluoperazine) and later trifluorinated
antidepressants (fluoxetine and fluvoxamine) began with animal experim
ents in 1983. Using rats which have been treated with high oral doses
of fluphenazine over a period of three weeks in the beginning of these
experiments the measurement time was very long (up to 10 h). The appl
ication of better techniques using surface coils led to marked improve
ment of the signal Poise ratio and measurement times in animal experim
ents could be reduced to minutes. These results encouraged us and othe
r groups to perform experiments in humans to detect and try to estimat
e brain levels of trifluorinated neuroleptics and antidepressants. The
present data of several research groups demonstrate that F-19 MR spec
troscopy has the potential of becoming a valuable tool for monitoring
drug levels at the site of action. The extension of the animal studies
to humans might facilitate a better treatment of schizophrenic and de
pressive patients.